GLS-409, an Antagonist of Both P2Y₁ and P2Y₁₂, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation.

ABSTRACT: Dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) P2Y₁₂ receptor antagonist reduces ischemic events in patients with acute coronary syndrome. Previous evidence from our group, obtained in a preclinical model of recurrent platelet-mediated thrombosis, demonstrated that GLS-409, a diadenosine tetraphosphate derivative that inhibits both P2Y₁ and P2Y₁₂ ADP receptors, may be a novel and promising antiplatelet drug candidate. However, the salutary antiplatelet effects of GLS-409 were accompanied by a trend toward an unfavorable increase in bleeding. The goals of this study were to: 1) provide proof-of-concept that the efficacy of GLS-409 may be maintained at lower dose(s), not accompanied by an increased propensity to bleeding; and 2) est

SUBMITTER: Smolensky Koganov E 

PROVIDER: S-EPMC6162268 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature